Payment overview · 2025
General Payments
$4,686.44
196 reported records · 35 companies
Healthcare provider profile · identity verified
Victor Faradji, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · MIAMI, FL · NPI 1851354807
Verified facts
What the public records show
CMS Open Payments records show Victor Faradji, MD received $4,686.44 in general payments during 2025 across 196 reported records.
ABBVIE INC. accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Inbrija, Nuplazid, Ongentys, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ubrelvy by this doctor in 2024.
ACADIA Pharmaceuticals Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUPLAZID as an associated drug or biological on 20845 records involving 6448 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Nuplazid by this doctor in 2024.
Amneal Pharmaceuticals LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ONGENTYS as an associated drug or biological on 728 records involving 311 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ongentys by this doctor in 2024.
Merz Pharmaceuticals, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INBRIJA as an associated drug or biological on 4307 records involving 2211 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Inbrija by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $955.47 | 20.4% | 47 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $529.64 | 11.3% | 14 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $373.02 | 8.0% | 22 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $329.45 | 7.0% | 8 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $281.12 | 6.0% | 8 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $278.22 | 5.9% | 14 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $201.17 | 4.3% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $170.73 | 3.6% | 9 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $128.35 | 2.7% | 5 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $104.98 | 2.2% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $103.35 | 2.2% | 6 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $99.27 | 2.1% | 3 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $97.72 | 2.1% | 4 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $97.55 | 2.1% | 5 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $83.81 | 1.8% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $78.94 | 1.7% | 4 | 2025 |
| C2N Diagnostics, LLC | Unresolved — no canonical attribution shown | $77.69 | 1.7% | 4 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $70.51 | 1.5% | 3 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $65.00 | 1.4% | 1 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $64.19 | 1.4% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $58.76 | 1.2% | 3 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $53.89 | 1.1% | 2 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $53.72 | 1.1% | 1 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $50.00 | 1.1% | 1 | 2025 |
| MDD US Operations, LLC | Unresolved — no canonical attribution shown | $48.30 | 1.0% | 2 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $38.91 | 0.8% | 2 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $33.96 | 0.7% | 2 | 2025 |
| SK Life Science, Inc. |
SK Life Science, Inc. exact · evidence 2025-04-03 |
$25.20 | 0.5% | 1 | 2025 |
| InSightec,Inc | Unresolved — no canonical attribution shown | $23.31 | 0.5% | 1 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $21.41 | 0.5% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.53 | 0.4% | 1 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $18.19 | 0.4% | 1 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $17.86 | 0.4% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$17.53 | 0.4% | 1 | 2025 |
| GE HEALTHCARE | Unresolved — no canonical attribution shown | $14.69 | 0.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,511.44 | 195 |
| Consulting Fee | $175.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $420.64 | 19 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $370.88 | 23 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $329.45 | 8 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $315.07 | 16 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $315.07 | 16 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $296.24 | 21 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $281.12 | 8 | 2025 |
Source payment records
|
|||||
| Briviact Normalized: briviact |
Drug | UCB, Inc. | $271.94 | 7 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $227.37 | 11 | 2025 |
Source payment records
|
|||||
| VYALEV Normalized: vyalev |
Drug | ABBVIE INC. | $219.15 | 5 | 2025 |
Source payment records
|
|||||
| WAINUA Normalized: wainua |
Drug | AstraZeneca Pharmaceuticals LP | $201.17 | 9 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $156.45 | 8 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $155.14 | 3 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $148.40 | 8 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $128.35 | 5 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $104.98 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $103.35 | 6 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $102.56 | 4 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $99.27 | 3 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $97.72 | 4 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $88.00 | 5 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $83.81 | 3 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $78.94 | 4 | 2025 |
Source payment records
|
|||||
| PRECIVITYAD2 Normalized: precivityad2 |
Device | C2N Diagnostics, LLC | $77.69 | 4 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $70.51 | 3 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $65.00 | 1 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $64.19 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $58.76 | 3 | 2025 |
Source payment records
|
|||||
| OCTAGAM IMMUNE GLOBULIN (HUMAN) Normalized: octagam immune globulin human |
Drug | PFIZER INC. | $57.95 | 6 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $57.95 | 6 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $54.72 | 3 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $53.72 | 1 | 2025 |
Source payment records
|
|||||
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $50.00 | 1 | 2025 |
Source payment records
|
|||||
| ZEPOSIA Normalized: zeposia |
Drug | Celgene Corporation | $33.96 | 2 | 2025 |
Source payment records
|
|||||
| Apokyn Normalized: apokyn |
Drug | MDD US Operations, LLC | $24.39 | 1 | 2025 |
Source payment records
|
|||||
| Exablate Normalized: exablate |
Device | InSightec,Inc | $23.31 | 1 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $21.41 | 1 | 2025 |
Source payment records
|
|||||
| ONGENTYS Normalized: ongentys |
Drug | Amneal Pharmaceuticals LLC | $21.12 | 1 | 2025 |
Source payment records
|
|||||
| SKYCLARYS Normalized: skyclarys |
Drug | Biogen, Inc. | $17.86 | 1 | 2025 |
Source payment records
|
|||||
| CREXONT Normalized: crexont |
Drug | Amneal Pharmaceuticals LLC | $17.79 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $17.53 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| INBRIJA inbrija |
2025 | Inbrija | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NUPLAZID nuplazid |
2025 | Nuplazid | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ONGENTYS ongentys |
2025 | Ongentys | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| ACADIA Pharmaceuticals Inc Exact reporting entity; no affiliate inference |
2025 | NUPLAZID open payments reported associated product |
CMS Open Payments — General Payments 20845 supporting records · 6448 recipient NPIs · example record 1247763852 |
Nuplazid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Amneal Pharmaceuticals LLC Exact reporting entity; no affiliate inference |
2025 | ONGENTYS open payments reported associated product |
CMS Open Payments — General Payments 728 supporting records · 311 recipient NPIs · example record 1220525547 |
Ongentys · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merz Pharmaceuticals, LLC Exact reporting entity; no affiliate inference |
2025 | INBRIJA open payments reported associated product |
CMS Open Payments — General Payments 4307 supporting records · 2211 recipient NPIs · example record 1232555387 |
Inbrija · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Donepezil Hcl | Donepezil Hcl | 246 | 84 |
| Gabapentin | Gabapentin | 147 | 56 |
| Trazodone Hcl | Trazodone Hcl | 85 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 82 | 22 |
| Memantine Hcl | Memantine Hcl | 59 | 17 |
| Pregabalin | Pregabalin | 46 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 45 | 15 |
| Rasagiline Mesylate | Rasagiline Mesylate | 33 | suppressed |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 28 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 27 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 27 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 25 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | 15 |
| Meloxicam | Meloxicam | 22 | suppressed |
| Folic Acid | Folic Acid | 21 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Rivastigmine | Rivastigmine | 19 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 16 | suppressed |
| Lacosamide | Lacosamide | 16 | suppressed |
| Ramelteon | Ramelteon | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Levetiracetam | Levetiracetam | 15 | suppressed |
| Ongentys | Opicapone | 14 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 13 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Inbrija | Levodopa | 12 | suppressed |
| Phenobarbital | Phenobarbital | 12 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $4,686.44 · 196 records | ABBVIE INC. | AMPYRA, AUSTEDO XR, Apokyn, BOTOX, BRIUMVI, Briviact, CREXONT, DAXXIFY, Exablate, HYQVIA, INBRIJA, INGREZZA, KESIMPTA, KISUNLA, Leqembi, MOUNJARO, NEURACEQ, NUPLAZID, NURTEC ODT, Nayzilam, OCTAGAM IMMUNE GLOBULIN (HUMAN), ONGENTYS, PANZYGA, PRECIVITYAD2, QULIPTA, REXULTI, Rystiggo, SKYCLARYS, Symbravo, UBRELVY, ULTOMIRIS, UPLIZNA, VALTOCO, VYALEV, VYEPTI, VYVGART HYTRULO, WAINUA, WAKIX, WATCHMAN FLX, Xeomin, ZAVZPRET, ZEPBOUND, ZEPOSIA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Inbrija play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error